×
About 1,615 results

ALLMedicine™ Apolipoprotein A-I Center

Research & Reviews  611 results

Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
https://clinicaltrials.gov/ct2/show/NCT02315586

Sep 26th, 2022 - Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease that occurs primarily in older individuals, 55 to 75 years of age, with a median survival of approximately 3 years from time of diagnosis. At present, there are no effective trea...

The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I.
https://doi.org/10.1016/j.beem.2022.101689
Best Practice & Research. Clinical Endocrinology & Metabo... Thomas SR, Zhang Y et. al.

Aug 26th, 2022 - The high density lipoprotein (HDL) fraction of human plasma consists of multiple subpopulations of spherical particles that are structurally uniform, but heterogeneous in terms of size, composition and function. Numerous epidemiological studies ha...

ABCA1 is an extracellular phospholipid translocase.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381790
Nature Communications; Segrest JP, Tang C et. al.

Aug 17th, 2022 - Production of high density lipoprotein (HDL) requires ATP-binding cassette transporter A1 (ABCA1) to drive phospholipid (PL) from the plasma membrane into extracellular apolipoprotein A-I. Here, we use simulations to show that domains of ABCA1 wit...

Lipid levels in midlife and risk of atrial fibrillation over 3 decades-Experience from ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371362
PLoS Medicine; Ding M, Wennberg A et. al.

Aug 12th, 2022 - The role of cholesterol levels in the development of atrial fibrillation (AF) is still controversial. In addition, whether and to what extent apolipoproteins are associated with the risk of AF is rarely studied. In this study, we aimed to investig...

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
https://clinicaltrials.gov/ct2/show/NCT04216342

Aug 11th, 2022 - Cardiovascular disease (CVD) is one of the leading causes of death worldwide and elevated levels of cholesterol and triglycerides on plasma lipoproteins are major contributing risk factors. Therapeutic agents that increase High Density Lipoprotein...

see more →

Clinicaltrials.gov  22 results

Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
https://clinicaltrials.gov/ct2/show/NCT02315586

Sep 26th, 2022 - Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease that occurs primarily in older individuals, 55 to 75 years of age, with a median survival of approximately 3 years from time of diagnosis. At present, there are no effective trea...

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
https://clinicaltrials.gov/ct2/show/NCT04216342

Aug 11th, 2022 - Cardiovascular disease (CVD) is one of the leading causes of death worldwide and elevated levels of cholesterol and triglycerides on plasma lipoproteins are major contributing risk factors. Therapeutic agents that increase High Density Lipoprotein...

Families-At-risk for Interstitial Lung Disease Study
https://clinicaltrials.gov/ct2/show/NCT03641742

Jul 21st, 2022 - The NHLBI has prioritized research focused on the primary prevention of chronic lung diseases, including ILD. The overall goal of this study is to conduct studies preparatory to and requisite for the testing of ILD preventative interventions. In t...

Nutrigenetic Intervention on Blood Lipid Markers and Body Composition of Adults With Overweight and Obesity
https://clinicaltrials.gov/ct2/show/NCT05210023

Jan 27th, 2022 - After the selection of the population, the patients undergo a molecular diagnosis: DNA will be extracted from peripheral blood with the High Pure PCR (Polymerase Chain Reaction) Template Preparation Kit (Roche). Then certain polymorphisms will be ...

Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)
https://clinicaltrials.gov/ct2/show/NCT02713880

May 5th, 2021 - Diseases of diverse etiology can be correlated to the term "polyneuropathy"(PNP). The pathogenesis may be of inflammatory, autoimmune, metabolic, toxic or hereditary nature. Careful clinical and electrodiagnostic assessment, with attention to the ...

see more →

News  13 results

ApoA-I Therapies Flop for Plaque Reduction
https://www.medpagetoday.com/cardiology/atherosclerosis/74221

Jul 25th, 2018 - Action Points Two studies of recombinant apolipoprotein A-I (the major HDL apolipoprotein) products failed to show an effect on coronary plaque volume assessed by intravascular ultrasound (IVUS). Note that based on these studies, the development o...

No Plaque Reduction With Mimetic HDL Agent in ACS: CARAT Phase 2 Trial
https://www.medscape.com/viewarticle/877757

Mar 27th, 2017 - WASHINGTON, DC — Infusing an engineered HDL-cholesterol mimetic into patients who recently have had acute coronary syndrome (ACS) did not reduce the volume of plaque in arteries as measured by intravascular ultrasound (IVUS) compared with placebo,...

Favorable Lipid Changes Seen with Baricitinib
https://www.medpagetoday.com/rheumatology/arthritis/62498

Jan 12th, 2017 - Action Points Baricitinib, an investigational reversible inhibitor of tyrosine kinases JAK 1 and JAK2 signaling, increases the level of serum lipids, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-...

VIDEO: MILANO-PILOT marks end of the road for HDL mimetic
https://www.mdedge.com/chestphysician/article/119301/lipid-disorders/video-milano-pilot-marks-end-road-hdl-mimetic
Susan London, MDedge News

Dec 2nd, 2016 - NEW ORLEANS – The future doesn’t look bright at the moment for use of agents that mimic HDL cholesterol to reverse coronary disease, based on disappointing results of the randomized, phase II MILANO-PILOT trial. Among 120 patients with recent acut.

Mono/Combo Therapy Improves HDL in Early RA
https://www.medpagetoday.com/rheumatology/arthritis/59675

Aug 14th, 2016 - Action Points Note that this secondary analysis of a clinical trial in patients with rheumatoid arthritis found that decreases in inflammatory markers were associated with improvement in HDL function. While the mechanism is not entirely clear, imp...

see more →